Chris Cooley
Stock Analyst at Stephens & Co.
(3.09)
# 1,221
Out of 5,111 analysts
55
Total ratings
71.05%
Success rate
44.18%
Average return
Main Sectors:
Stocks Rated by Chris Cooley
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VCEL Vericel | Maintains: Overweight | $39 → $42 | $35.50 | +18.31% | 2 | May 11, 2023 | |
| ALGN Align Technology | Maintains: Overweight | $500 → $375 | $162.89 | +130.22% | 7 | Jul 28, 2022 | |
| COO The Cooper Companies | Maintains: Overweight | $125 → $115 | $81.04 | +41.91% | 9 | Jun 3, 2022 | |
| ALC Alcon | Upgrades: Overweight | $86 → $92 | $79.02 | +16.43% | 4 | May 12, 2022 | |
| PLSE Pulse Biosciences | Maintains: Overweight | $14 → $12 | $14.23 | -15.67% | 2 | Apr 1, 2022 | |
| ANIK Anika Therapeutics | Downgrades: Equal-Weight | n/a | $9.51 | - | 2 | Mar 9, 2022 | |
| ESTA Establishment Labs Holdings | Maintains: Overweight | $88 → $90 | $74.15 | +21.38% | 3 | Nov 10, 2021 | |
| STE STERIS | Maintains: Overweight | $255 → $270 | $253.03 | +6.71% | 5 | Nov 4, 2021 | |
| GKOS Glaukos | Upgrades: Overweight | $60 → $68 | $113.76 | -40.23% | 5 | Nov 3, 2021 | |
| AVNS Avanos Medical | Downgrades: Equal-Weight | $60 → $45 | $11.62 | +287.26% | 2 | Aug 4, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $425 → $275 | $124.87 | +120.23% | 5 | Mar 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $56 → $37 | $24.80 | +49.19% | 2 | Mar 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $75 → $60 | $66.37 | -9.60% | 3 | Mar 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $48 → $35 | $92.95 | -62.35% | 2 | Mar 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $60 → $81 | $288.73 | -71.95% | 2 | Feb 22, 2018 |
Vericel
May 11, 2023
Maintains: Overweight
Price Target: $39 → $42
Current: $35.50
Upside: +18.31%
Align Technology
Jul 28, 2022
Maintains: Overweight
Price Target: $500 → $375
Current: $162.89
Upside: +130.22%
The Cooper Companies
Jun 3, 2022
Maintains: Overweight
Price Target: $125 → $115
Current: $81.04
Upside: +41.91%
Alcon
May 12, 2022
Upgrades: Overweight
Price Target: $86 → $92
Current: $79.02
Upside: +16.43%
Pulse Biosciences
Apr 1, 2022
Maintains: Overweight
Price Target: $14 → $12
Current: $14.23
Upside: -15.67%
Anika Therapeutics
Mar 9, 2022
Downgrades: Equal-Weight
Price Target: n/a
Current: $9.51
Upside: -
Establishment Labs Holdings
Nov 10, 2021
Maintains: Overweight
Price Target: $88 → $90
Current: $74.15
Upside: +21.38%
STERIS
Nov 4, 2021
Maintains: Overweight
Price Target: $255 → $270
Current: $253.03
Upside: +6.71%
Glaukos
Nov 3, 2021
Upgrades: Overweight
Price Target: $60 → $68
Current: $113.76
Upside: -40.23%
Avanos Medical
Aug 4, 2021
Downgrades: Equal-Weight
Price Target: $60 → $45
Current: $11.62
Upside: +287.26%
Mar 23, 2020
Maintains: Overweight
Price Target: $425 → $275
Current: $124.87
Upside: +120.23%
Mar 23, 2020
Maintains: Overweight
Price Target: $56 → $37
Current: $24.80
Upside: +49.19%
Mar 23, 2020
Maintains: Overweight
Price Target: $75 → $60
Current: $66.37
Upside: -9.60%
Mar 23, 2020
Maintains: Overweight
Price Target: $48 → $35
Current: $92.95
Upside: -62.35%
Feb 22, 2018
Maintains: Equal-Weight
Price Target: $60 → $81
Current: $288.73
Upside: -71.95%